Suppr超能文献

非转移性透明细胞肾细胞癌患者术后免疫细胞浸润异质性及预后能力

Non-Metastatic Clear Cell Renal Cell Carcinoma Immune Cell Infiltration Heterogeneity and Prognostic Ability in Patients Following Surgery.

作者信息

Shapiro Daniel D, Lozar Taja, Cheng Lingxin, Xie Elliot, Laklouk Israa, Lee Moon Hee, Huang Wei, Jarrard David F, Allen Glenn O, Hu Rong, Kinoshita Toshi, Esbona Karla, Lambert Paul F, Capitini Christian M, Kendziorski Christina, Abel Edwin Jason

机构信息

Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.

William S. Middleton Memorial Veterans Hospital, Madison, WI 53705, USA.

出版信息

Cancers (Basel). 2024 Jan 23;16(3):478. doi: 10.3390/cancers16030478.

Abstract

Predicting which patients will progress to metastatic disease after surgery for non-metastatic clear cell renal cell carcinoma (ccRCC) is difficult; however, recent data suggest that tumor immune cell infiltration could be used as a biomarker. We evaluated the quantity and type of immune cells infiltrating ccRCC tumors for associations with metastatic progression following attempted curative surgery. We quantified immune cell densities in the tumor microenvironment and validated our findings in two independent patient cohorts with multi-region sampling to investigate the impact of heterogeneity on prognostic accuracy. For non-metastatic ccRCC, increased CD8 T cell infiltration was associated with a reduced likelihood of progression to metastatic disease. Interestingly, patients who progressed to metastatic disease also had increased percentages of exhausted CD8 T cells. Finally, we evaluated the spatial heterogeneity of the immune infiltration and demonstrated that patients without metastatic progression had CD8 T cells in closer proximity to ccRCC cells. These data strengthen the evidence for CD8 T cell infiltration as a prognostic biomarker in non-metastatic ccRCC and demonstrate that multi-region sampling may be necessary to fully characterize immune infiltration within heterogeneous tumors. Tumor CD8 T cell infiltration should be investigated as a biomarker in adjuvant systemic therapy clinical trials for high-risk non-metastatic RCC.

摘要

预测哪些非转移性透明细胞肾细胞癌(ccRCC)患者在手术后会进展为转移性疾病很困难;然而,最近的数据表明肿瘤免疫细胞浸润可作为一种生物标志物。我们评估了浸润ccRCC肿瘤的免疫细胞的数量和类型,以探讨其与根治性手术后转移性进展的相关性。我们对肿瘤微环境中的免疫细胞密度进行了量化,并在两个采用多区域采样的独立患者队列中验证了我们的发现,以研究异质性对预后准确性的影响。对于非转移性ccRCC,CD8 T细胞浸润增加与进展为转移性疾病的可能性降低相关。有趣的是,进展为转移性疾病的患者中耗竭性CD8 T细胞的百分比也有所增加。最后,我们评估了免疫浸润的空间异质性,结果表明无转移性进展的患者的CD8 T细胞与ccRCC细胞的距离更近。这些数据进一步证明了CD8 T细胞浸润作为非转移性ccRCC预后生物标志物的证据,并表明可能需要进行多区域采样才能全面表征异质性肿瘤内的免疫浸润情况。在高危非转移性RCC的辅助全身治疗临床试验中,应将肿瘤CD8 T细胞浸润作为生物标志物进行研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b54e/10854750/da03fb770bab/cancers-16-00478-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验